aerosolized aztreonam
Phase 1Small molecule
aerosolized aztreonam is one of 12 small molecule programs targeting Advanced Non-Small Cell Lung Cancer. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
17 competitors in Advanced Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 3
PF-08634404
PfizerPhase 3
Fludara
SanofiPhase 2
Proleukin
IIovance Biotherapeutics, Inc.
Phase 2
Cytoxan
BBaxter Healthcare Corporation
Phase 2
Surufatinib
HHutchison Medipharma Limited
Phase 2
Fabhalta
RegeneronPreclinical
Libtayo
RegeneronPreclinical
Young TIL
NNational Cancer Institute (NCI)
Phase 2
Krazati
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for aerosolized aztreonam. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- NNational Cancer Institute (NCI)